U-Systems, Inc. announces technology licensing agreement with Siemens Healthcare

31 December 2008

U-Systems, Inc has announced a technology licensing agreement with the Ultrasound Business Unit of Siemens Medical Solutions USA, Inc.

The U-Systems’ somo•VIEWer advanced workstation for Automated Breast Ultrasound has been licensed for use with the newly introduced Siemens’ ACUSON S2000 Automated Breast Volume Scanner (ABVS).

This will allow physicians to obtain the comprehensive 3D view of the breast volume which features U-Systems’ intuitive anatomical coronal plane not available with conventional ultrasound systems.

"This license agreement will increase the adoption of automated breast ultrasound systems for women’s healthcare clinics wanting the most advanced imaging technologies," said Ron Ho, President and CEO of U-Systems.

"Women’s healthcare and breast imaging is strategic to both U-Systems and Siemens. We see significant advantages in leveraging Siemens’ marketing and ultrasound expertise with our advanced development competencies and look forward to this partnership.”

Siemens is a non-exclusive distributor for U-Systems’ technology and products, including the somo•v Automated 3D Breast Ultrasound System, somo•VIEWer Software & Workstation, and somo•v Patient Stabilizing Membranes.

“I am convinced that automated breast volume scanning can make a significant contribution in diagnostic confidence for women with dense breast tissue and inconclusive mammograms,” said Klaus Hambuechen, CEO, Ultrasound, Siemens Healthcare. “The coronal view provided by the somo•VIEWer offers a more understandable representation of the global anatomy and architecture of the breast, which will ultimately improve patient care and increase clinical workflow.”

U-Systems is dedicated to bringing technology solutions to women’s healthcare. In 2009, the company will be sponsoring a multi-center breast cancer screening study, somo•InSIGHT, with more than 20,000 women using its proprietary Automated Breast Ultrasound System (ABUS). The clinical study will evaluate the sensitivity and specificity of X-Ray Mammography (XRM) and Automated Breast Ultrasound (ABUS) together as compared to XRM alone, as a breast cancer screening method in women with greater than 50 percent parenchymal density.

Bookmark this page

To top